institutions, and NGOs, including outcomes of prior workshops and planning bodies. BOEM has partnered with the Blue World Research Institute to implement the questionnaire. The questionnaire comprises approximately 20 questions that ask respondents about: (1) their organization; (2) information on current monitoring and research activities, such as objective, location, scope, methods, timelines, outcomes and challenges, and on contributions to NARW conservation or impact reduction; (3) related ancillary information, such as type of study, next steps, and suggestions for priority topics for future funding; and (4) additional comments and discussion. The questionnaire avoids sensitive topics or matters that are commonly considered private. The results will be summarized as part of the NARW synthesis report.

Additionally, BOEM plans to conduct directed interviews of participants who indicate their willingness to provide additional feedback on future research priorities and management needs. This feedback will be compiled in a final report.

**OMB Control Number:** 1010–NEW

**Form Number:** None.

**Type of Review:** New.

**Respondents/Affected Public:** State (and Federal) government researchers, academic institutions, and NGOs.

**Total Estimated Number of Annual Responses:** 253 responses (213 questionnaire respondents and 40 interviewees).

**Total Estimated Number of Annual Burden Hours:** 111 hours (40 annual burden hours for interviews and 71 annual burden hours for questionnaire).

**Respondent’s Obligation:** Voluntary.

**Frequency of Collection:** On occasion.

**Total Estimated Annual Non-hour Burden Cost:** There is no non-hour cost burden associated with this collection.

**A Federal Register** notice with a 60-day public comment period on this proposed ICR was published on February 24, 2023 (88 FR 11953). BOEM received one public comment that opposed offshore wind energy projects and the use of sonar due to potential impacts on whales and dolphins. BOEM is committed to assessing and, to the extent possible, reducing the effects of potential environmental impacts on marine life and their habitats. The purpose of this strategy is to protect and promote the recovery of the NARW while responsibly developing offshore wind energy. No change in the burden was required as a result of the comment received.

BOEM is again soliciting comments on the proposed ICR. BOEM is especially interested in public comments addressing the following issues: (1) the collection necessary to the proper functions of BOEM; (2) what can BOEM do to ensure that this information is processed and used in a timely manner; (3) is the burden estimate accurate; (4) how might BOEM enhance the quality, utility, and clarity of the information to be collected; and (5) how might BOEM minimize the burden of this collection on the respondents, including minimizing the burden through the use of information technology?

Comments submitted in response to this notice are a matter of public record and will be available for public review on www.reginfo.gov. You should be aware that your entire comment—including your address, phone number, email address, or other personally identifiable information included in your comment—may be made publicly available. Even if BOEM withholds your information in the context of this ICR, your comment is subject to the Freedom of Information Act (FOIA). If your comment is requested under FOIA, your information will only be withheld if BOEM determines that a FOIA exemption to disclosure applies. BOEM will make such a determination in accordance with the Department of the Interior’s (DOI’s) FOIA regulations and applicable law.

In order for BOEM to consider withholding from disclosure your personally identifiable information, you must identify, in a cover letter, any information contained in your comments that, if released, would constitute a clearly unwarranted invasion of your personal privacy. You must also briefly describe any possible harmful consequence of the disclosure of information, such as embarrassment, injury, or other harm.

BOEM protects proprietary information in accordance with FOIA (5 U.S.C. 552) and DOI’s implementing regulations (43 CFR part 2).

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a valid OMB control number.

The authority for this action is the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.).

Karen Thundiyil,
Chief, Office of Regulations, Bureau of Ocean Energy Management.

**SUPPLEMENTARY INFORMATION:**
In accordance with 21 CFR 1301.34(a), this is notice that on July 11, 2023, Caligor Coghlan Pharma Services has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA–1243]

**Importer of Controlled Substances Application:** Caligor Coghlan Pharma Services

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Caligor Coghlan Pharma Services has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before September 11, 2023. Such persons may also file a written request for a hearing on the application on or before September 11, 2023.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.

**In accordance with 21 CFR 1301.34(a), this is notice that on July 11, 2023, Caligor Coghlan Pharma Services, 1500 Business Park Drive, Unit B, Bastrop, Texas 78602, applied to be registered as an importer of the following basic class(es) of controlled substance(s):**
The company plans to import the listed controlled substances as finished dosage units for use in clinical trials. No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

Claude Redd,
Acting Deputy Assistant Administrator.

**APPLICATION:** Chattem Chemicals, 3801 Saint Elmo Avenue, Chattanooga, Tennessee 37409–1237, is notice that on July 14, 2023, Chattem Chemicals has applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

<table>
<thead>
<tr>
<th>Controlled substance</th>
<th>Drug code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen ..........</td>
<td>54353</td>
<td></td>
</tr>
<tr>
<td>Methamphetamine ......</td>
<td>1105</td>
<td>II</td>
</tr>
<tr>
<td>4-Anilino-N-phenethyl-4-phenylacetone .......</td>
<td>8501</td>
<td>II</td>
</tr>
<tr>
<td>Phenylacetone ..............</td>
<td>8333</td>
<td>II</td>
</tr>
<tr>
<td>Cocaine ..................</td>
<td>9041</td>
<td>II</td>
</tr>
<tr>
<td>Poppy Straw Concentrate, Tapentadol .............</td>
<td>9670</td>
<td>II</td>
</tr>
</tbody>
</table>

The company plans to bulk manufacture the above listed controlled substance for research and development purposes only. No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

Claude Redd,
Acting Deputy Assistant Administrator.

**APPLICATION:** Continuum Pharmaceuticals, 256 West Cummings Park, Woburn, Massachusetts 01801, is notice that on July 6, 2023, Continuum Pharmaceuticals, 256 West Cummings Park, Woburn, Massachusetts 01801, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

<table>
<thead>
<tr>
<th>Controlled substance</th>
<th>Drug code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fentanyl ..............</td>
<td>9801</td>
<td>II</td>
</tr>
</tbody>
</table>

The company plans to bulk manufacture the above listed controlled substance for research and development purposes only. No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

Claude Redd,
Acting Deputy Assistant Administrator.

**APPLICATION:** Chattem Chemicals, 3801 Saint Elmo Avenue, Chattanooga, Tennessee 37409–1237, is notice that on July 14, 2023, Chattem Chemicals has applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

<table>
<thead>
<tr>
<th>Controlled substance</th>
<th>Drug code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen ..........</td>
<td>54353</td>
<td></td>
</tr>
<tr>
<td>Methamphetamine ......</td>
<td>1105</td>
<td>II</td>
</tr>
<tr>
<td>4-Anilino-N-phenethyl-4-phenylacetone .......</td>
<td>8501</td>
<td>II</td>
</tr>
<tr>
<td>Phenylacetone ..............</td>
<td>8333</td>
<td>II</td>
</tr>
<tr>
<td>Cocaine ..................</td>
<td>9041</td>
<td>II</td>
</tr>
<tr>
<td>Poppy Straw Concentrate, Tapentadol .............</td>
<td>9670</td>
<td>II</td>
</tr>
</tbody>
</table>

The company plans to import the listed controlled substances to manufacture bulk controlled substances for sale to its customers. The company plans to import an intermediate of Tapentadol (9780), to bulk manufacture Tapentadol for distribution to its customers. No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

Claude Redd,
Acting Deputy Assistant Administrator.